308 related articles for article (PubMed ID: 28942098)
21. Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer.
Ahn SK; Lee HB; Han W; Moon HG; You JM; Kim J; Han SW; Im SA; Kim TY; Noh DY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S391-7. PubMed ID: 26275780
[TBL] [Abstract][Full Text] [Related]
22. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
23. Patterns of Care in the Administration of Neo-adjuvant Chemotherapy for Breast Cancer. A Population-Based Study.
Vugts G; Maaskant-Braat AJ; Nieuwenhuijzen GA; Roumen RM; Luiten EJ; Voogd AC
Breast J; 2016 May; 22(3):316-21. PubMed ID: 26945566
[TBL] [Abstract][Full Text] [Related]
24. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB.
Liu J; Mao K; Jiang S; Jiang W; Chen K; Kim BY; Liu Q; Jacobs LK
Oncotarget; 2016 Apr; 7(17):24848-59. PubMed ID: 26709538
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors of locally advanced breast cancer patients receiving neoadjuvant and adjuvant chemotherapy.
Akhsan A; Aryandono T
Asian Pac J Cancer Prev; 2010; 11(3):759-61. PubMed ID: 21039049
[TBL] [Abstract][Full Text] [Related]
26. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
27. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
28. Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012.
Wapnir IL; Kurian AW; Lichtensztajn DY; Clarke CA; Gomez SL
Ann Surg; 2017 Aug; 266(2):353-360. PubMed ID: 27611617
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment.
Buonomo OC; Grasso A; Pistolese CA; Anemona L; Portarena I; Meucci R; Morando L; Deiana C; Materazzo M; Vanni G
Anticancer Res; 2020 Jan; 40(1):281-286. PubMed ID: 31892577
[TBL] [Abstract][Full Text] [Related]
31. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
32. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.
van der Heiden-van der Loo M; de Munck L; Sonke GS; van Dalen T; van Diest PJ; van den Bongard HJ; Peeters PH; Rutgers EJ
Eur J Cancer; 2015 May; 51(8):915-21. PubMed ID: 25857549
[TBL] [Abstract][Full Text] [Related]
33. Assessment of prognostic factors for locally advanced breast cancer.
Chakrabarti A; Dasgupta P; Haldar D; Acharyya S; Gangopadhyay S
J Indian Med Assoc; 2012 May; 110(5):284-6. PubMed ID: 23360018
[TBL] [Abstract][Full Text] [Related]
34. Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands.
Heeg E; Jensen MB; Mureau MAM; Ejlertsen B; Tollenaar RAEM; Christiansen PM; Vrancken Peeters MTFD
Breast Cancer Res Treat; 2020 Aug; 182(3):709-718. PubMed ID: 32524354
[TBL] [Abstract][Full Text] [Related]
35. Variation in management of early breast cancer in the Netherlands, 2003-2006.
van Steenbergen LN; van de Poll-Franse LV; Wouters MW; Jansen-Landheer ML; Coebergh JW; Struikmans H; Tjan-Heijnen VC; van de Velde CJ
Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S36-43. PubMed ID: 20620013
[TBL] [Abstract][Full Text] [Related]
36. Clinical study of the relationship between γ-synuclein and the response of neoadjuvant chemotherapy in breast cancer.
Wan F; Dong L; Zhang F; Wang Y; Chen F; Ni S; Chen Y; Long J
J Int Med Res; 2013 Jun; 41(3):743-53. PubMed ID: 23696593
[TBL] [Abstract][Full Text] [Related]
37. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.
Bufi E; Belli P; Di Matteo M; Giuliani M; Tumino M; Rinaldi P; Nardone L; Franceschini G; Mulé A; Bonomo L
Clin Breast Cancer; 2016 Dec; 16(6):e193-e201. PubMed ID: 27431459
[TBL] [Abstract][Full Text] [Related]
38. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
39. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
[TBL] [Abstract][Full Text] [Related]
40. Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.
Klein J; Tran W; Watkins E; Vesprini D; Wright FC; Look Hong NJ; Ghandi S; Kiss A; Czarnota GJ
BMC Cancer; 2019 Apr; 19(1):306. PubMed ID: 30943923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
